The estimated Net Worth of Jennifer Zachary is at least $33.3 Million dollars as of 2 February 2024. Ms. Zachary owns over 49,499 units of Merck & Co Inc stock worth over $3,333,128 and over the last 7 years she sold MRK stock worth over $24,958,720. In addition, she makes $5,045,720 as Executive Vice President, General Counsel und Corporate Secretary at Merck & Co Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Zachary MRK stock SEC Form 4 insiders trading
Jennifer has made over 7 trades of the Merck & Co Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 49,499 units of MRK stock worth $6,284,888 on 2 February 2024.
The largest trade she's ever made was selling 165,255 units of Merck & Co Inc stock on 28 October 2022 worth over $16,423,042. On average, Jennifer trades about 17,192 units every 91 days since 2018. As of 2 February 2024 she still owns at least 29,057 units of Merck & Co Inc stock.
You can see the complete history of Ms. Zachary stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jennifer Zachary biography
Jennifer L. Zachary serves as Executive Vice President, General Counsel, Corporate Secretary of the Company. Zachary is currently a partner at Covington & Burling in the firm's food, drug, and device practice group where she advises a wide range of manufacturers and industry trade associations on FDA's requirements for the development, manufacture, and distribution of prescription and over-the-counter drugs, biologics, and medical devices. Zachary began her career in FDA's Office of Chief Counsel, where she served as an Associate Chief Counsel for Enforcement from 2005 to 2011. Zachary also served as a Special Assistant U.S. Attorney in the Civil Division of the U.S. Attorney's Office for the District of Columbia.
What is the salary of Jennifer Zachary?
As the Executive Vice President, General Counsel und Corporate Secretary of Merck & Co Inc, the total compensation of Jennifer Zachary at Merck & Co Inc is $5,045,720. There are 4 executives at Merck & Co Inc getting paid more, with Kenneth Frazier having the highest compensation of $27,648,500.
How old is Jennifer Zachary?
Jennifer Zachary is 42, she's been the Executive Vice President, General Counsel und Corporate Secretary of Merck & Co Inc since 2020. There are 27 older and no younger executives at Merck & Co Inc. The oldest executive at Merck & Co Inc is Thomas Cech, 73, who is the Independent Director.
What's Jennifer Zachary's mailing address?
Jennifer's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Insiders trading at Merck & Co Inc
Over the last 15 years, insiders at Merck & Co Inc have traded over $138,980,380 worth of Merck & Co Inc stock and bought 48,209 units worth $1,563,736 . The most active insiders traders include Wendell P Weeks, Kenneth C Frazier und Douglas M Jr Baker. On average, Merck & Co Inc executives and independent directors trade stock every 15 days with the average trade being worth of $5,050,222. The most recent stock trade was executed by Chirfi Guindo on 5 August 2024, trading 36,901 units of MRK stock currently worth $4,250,995.
What does Merck & Co Inc do?
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.
What does Merck & Co Inc's logo look like?
Complete history of Ms. Zachary stock trades at Regenxbio Inc und Merck & Co Inc
Merck & Co Inc executives and stock owners
Merck & Co Inc executives and other stock owners filed with the SEC include:
-
Kenneth Frazier,
Chairman of the Board, President, Chief Executive Officer -
Roger Perlmutter,
Executive Vice President, President - Merck Research Laboratories -
Robert Davis,
Executive Vice President, Global Services, Chief Financial Officer -
Sanat Chattopadhyay,
Executive Vice President and President - Merck Manufacturing Division -
Jennifer Zachary,
Executive Vice President, General Counsel, Corporate Secretary -
Kenneth C. Frazier,
Exec. Chairman -
Robert M. Davis,
Pres, CEO & Director -
Jennifer L. Zachary,
Exec. VP, Gen. Counsel & Corp. Sec. -
Sanat Chattopadhyay,
Exec. VP & Pres of Merck Manufacturing Division -
Thomas Cech,
Independent Director -
Leslie Brun,
Lead Independent Director -
Pamela Craig,
Independent Director -
Thomas Glocer,
Independent Director -
Paul Rothman,
Independent Director -
Peter Wendell,
Independent Director -
Inge Thulin,
Independent Director -
Patricia Russo,
Independent Director -
Mary Coe,
Independent Director -
Kathy Warden,
Independent Director -
Christine Seidman,
Independent Director -
Michael Fleming,
Senior Vice President, Chief Ethics and Compliance Officer -
Rita Karachun,
Senior Vice President Finance - Global Controller -
Julie Gerberding,
Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health -
Richard DeLuca,
Executive Vice President, President - Merck Animal Health -
Franklin Clyburn,
Executive Vice President, Chief Commercial Officer -
Michael Nally,
Executive Vice President, Chief Marketing Officer -
Steven Mizell,
Executive Vice President, Chief Human Resources Officer, Human Resources -
Cristal N. Downing,
Exec. VP and Chief Communications & Public Affairs Officer -
Michael W. Fleming,
Sr. VP and Chief Ethics & Compliance Officer -
Peter Dannenbaum,
VP of Investor Relations -
Jennifer Mauer,
VP of Global Communications -
Peter Dannenbaum CFA,
VP of Investor Relations -
David Michael Williams,
Chief Information & Digital Officer -
Caroline Litchfield,
Exec. VP & CFO -
Rochelle B Lazarus,
Director -
Craig B. Thompson,
Director -
Adam H Schechter,
EVP & Pres-Global Human Health -
Adele D Ambrose,
V-P & Chief Com. Officer -
Clark Golestani,
EVP & Chief Info Officer -
John H Noseworthy,
Director -
Wendell P Weeks,
Director -
Michael J Holston,
EVP, Chief Ethics & Compl Ofcr -
Carlos E Represas,
Director -
C Robert Kidder,
Director -
Weir Mirian M Graddick,
Exec. V-P, Human Resources -
Ashley Watson,
SVP Chief Ethics & Com Officer -
Frank Clyburn,
EVP & Pres ? Human Health -
James H Scholefield,
EVP,Chief Info&Digital Officer -
Joseph Romanelli,
President, Human Health Int?l -
Stephen Mayo,
Director -
Dean Y Li,
Executive VP & President, MRL -
David Michael Williams,
EVP,Chief Info&Digital Officer -
William B Jr Harrison,
Director -
Michael Rosenblatt,
Exec V-P & Chief Med Officer -
John Canan,
Senior V-P, Controller -
Stanley F Barshay,
Exec V-P Consumer Health Care -
Willie A Deese,
Exec. V-P and Pres., MMD -
Anne M Tatlock,
Director -
Samuel O Md Thier,
Director -
Mervyn Turner,
Chief Strategy Officer -
Willam N Kelley,
Director -
Richard S Iii Bowles,
Exe V-P & Chief Compl Officer -
Peter S Kim,
Exec. V-P and Pres., MRL -
Thomas E Shenk,
Director -
Bridgette P Heller,
Exe.VP & Pres.Con.Hlth.Care -
Raul E Kohan,
Exe V-P & Pres, Animal Health -
Steven F Goldstone,
Director -
Harry R Jacobson,
Director -
Richard T Clark,
Chairman, President and CEO -
Peter N Kellogg,
Exec. V.P. & C.F.O -
Bruce N Kuhlik,
Exec. V.P. and General Counsel -
Cuong V Do,
EVP & Chief Strategy Officer -
J Chris Scalet,
Exe. VP, Global Services & CIO -
Risa J Lavizzo Mourey,
Director -
Johannes Jacobus Oosthuizen,
President, U.S. Market -
Caroline Litchfield,
EVP & CFO -
Lisa Le Cointe Cephas,
SVP Chief Ethics & Com Officer -
Michael A Klobuchar,
EVP - Chief Strategy Officer -
Arpa Garay,
SVP Human Health Global Mktg. -
Cristal N Downing,
Chief Comm. & Public Afrs Ofcr -
Douglas M Jr Baker,
Director -
Chirfi Guindo,
Chief Marketing Officer -
Dalton Smart,
SVP Fin. - Global Controller -
Betty D Larson,
EVP, Chief HR Officer